Log In
BCIQ
Print this Print this
 

CD101 IV (formerly Biafungin, SP 3025)

  Manage Alerts
Collapse Summary General Information
Company Cidara Therapeutics Inc.
DescriptionEchinocandin antifungal
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationCandida
Indication DetailsTreat and prevent invasive fungal infections; Treat and prevent systemic Candida infections; Treat candidemia
Regulatory Designation U.S. - Fast Track (Treat candidemia);
U.S. - Fast Track (Treat and prevent invasive fungal infections);
U.S. - Orphan Drug (Treat and prevent invasive fungal infections);
U.S. - Orphan Drug (Treat candidemia);
U.S. - Qualified Infectious Disease Program (Treat candidemia);
U.S. - Qualified Infectious Disease Program (Treat and prevent invasive fungal infections)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today